236 related articles for article (PubMed ID: 29226728)
1. The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.
Liu J; Wang LN
Drug Deliv; 2018 Nov; 25(1):43-48. PubMed ID: 29226728
[TBL] [Abstract][Full Text] [Related]
2. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
3. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
[TBL] [Abstract][Full Text] [Related]
4. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
[TBL] [Abstract][Full Text] [Related]
5. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Moore DH
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD001447. PubMed ID: 22419278
[TBL] [Abstract][Full Text] [Related]
6. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Moore DH
Cochrane Database Syst Rev; 2001; (4):CD001447. PubMed ID: 11687111
[TBL] [Abstract][Full Text] [Related]
7. Riluzole for the treatment of amyotrophic lateral sclerosis.
Saitoh Y; Takahashi Y
Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone.
Liu J; Wang LN
CNS Drugs; 2014 Jan; 28(1):63-8. PubMed ID: 24242074
[TBL] [Abstract][Full Text] [Related]
9. [Adverse efects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis].
Roch-Torreilles I; Camu W; Hillaire-Buys D
Therapie; 2000; 55(2):303-12. PubMed ID: 10967703
[TBL] [Abstract][Full Text] [Related]
10. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Moore DH
Cochrane Database Syst Rev; 2000; (2):CD001447. PubMed ID: 10796796
[TBL] [Abstract][Full Text] [Related]
11. Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions-The CAESAR study.
Giometto S; Finocchietti M; Paoletti O; Lombardi N; Celani MG; Sciancalepore F; Lucenteforte E; Kirchmayer U;
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5736. PubMed ID: 38014926
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.
Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J
Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992
[TBL] [Abstract][Full Text] [Related]
14. Reversible granulocytopenia in association with riluzole therapy.
North WA; Khan AM; Yamase HT; Sporn JR
Ann Pharmacother; 2000 Mar; 34(3):322-4. PubMed ID: 10917377
[TBL] [Abstract][Full Text] [Related]
15. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
[TBL] [Abstract][Full Text] [Related]
16. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis.
Bensimon G; Lacomblez L; Delumeau JC; Bejuit R; Truffinet P; Meininger V;
J Neurol; 2002 May; 249(5):609-15. PubMed ID: 12021952
[TBL] [Abstract][Full Text] [Related]
17. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis.
Morren JA; Galvez-Jimenez N
Expert Opin Investig Drugs; 2012 Mar; 21(3):297-320. PubMed ID: 22303913
[TBL] [Abstract][Full Text] [Related]
18. [Tolerance of riluzole in a phase IIIb clinical trial].
Lacomblez L; Dib M; Doppler V; Faudet A; Robin V; Salachas F; Bensimon G; Meininger V
Therapie; 2002; 57(1):65-71. PubMed ID: 12090150
[TBL] [Abstract][Full Text] [Related]
19. Riluzole-induced recurrent pancreatitis.
Falcão de Campos C; de Carvalho M
J Clin Neurosci; 2017 Nov; 45():153-154. PubMed ID: 28867362
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis.
de Boer JN; Vingerhoets C; Hirdes M; McAlonan GM; Amelsvoort TV; Zinkstok JR
Psychiatry Res; 2019 Aug; 278():294-302. PubMed ID: 31254879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
